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PAtherosclerosis
s Plasma Oxidized Low-Density
ipoprotein, Measured With the Widely
sed Antibody 4E6, an Independent Predictor
f Coronary Heart Disease Among U.S. Men and Women?
ianying Wu, MD, PHD,* Walter C. Willett, MD, DRPH,*†‡ Nader Rifai, PHD, Iris Shai, PHD,*
oAnn E. Manson, MD, DRPH,†‡§ Eric B. Rimm, SCD*†‡
oston, Massachusetts
OBJECTIVES Our aim was to examine whether circulating oxidized low-density lipoprotein (oxLDL) is a
predictor of coronary heart disease (CHD) independent of lipid markers and to compare
oxLDL, apolipoprotein B100 (apoB), and total cholesterol (TC)/high-density lipoprotein-
cholesterol (HDL-C) ratio as predictors of CHD.
BACKGROUND Measurement of circulating oxLDL with antibody 4E6, has been widely used in many
studies; however, few large prospective studies have examined whether this marker is a
predictor of CHD independent of lipids and compared oxLDL with other important lipid
predictors.
METHODS After 6 years of follow-up among 18,140 men from the HPFS (Health Professionals
Follow-up Study) and 8 years among 32,826 women from the Nurses’ Health Study who
provided blood samples at baseline, we identified incident nonfatal myocardial infarction or
fatal CHD in 266 men and 235 women. Each case was matched with two control subjects by
age, smoking, and time of blood draw. The oxLDL was measured via enzyme-linked
immunosorbent assay with antibody 4E6 against oxidized apoB.
RESULTS Among both men and women, oxLDL was significantly related to risk of CHD in
multivariate analysis before adjustment for any lipid markers. However, when oxLDL, LDL
cholesterol, HDL-C, and triglycerides were mutually adjusted, oxLDL was no longer
predictive. When oxLDL and apoB were mutually adjusted, only apoB was predictive of
CHD. Similar results were found when oxLDL and TC/HDL-C ratio were mutually
adjusted.
CONCLUSIONS Our results suggest that circulating oxLDL, measured with antibody 4E6, is not an
independent overall predictor of CHD after adjustment of lipid markers and is less predictive
in development of CHD than apoB and TC/HDL-C ratio. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.057973–9) © 2006 by the American College of Cardiology Foundation
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Cxidative stress and oxidized low-density lipoprotein
oxLDL) have been proposed to play an important role in
he development of atherosclerosis (1,2). The oxLDL is
resent in atherosclerotic lesions from humans (3,4) and
nimals (5); however, the importance of circulating oxLDL
s a predictor of subsequent clinical coronary events has not
een confirmed.
See page 980
Reliable markers of oxLDL for epidemiologic studies are
imited. Biopsy samples from atherosclerotic lesions for
From the *Department of Nutrition and the †Department of Epidemiology,
arvard School of Public Health, ‡Channing Laboratory, §Division of Preventive
edicine, Department of Medicine, Harvard Medical School and Brigham &
omen’s Hospital, and the Department of Laboratory Medicine, Children’s
ospital and Harvard Medical School, Boston, Massachusetts. This work was
upported by National Institutes of Health grants CA87969, HL34594, CA55075,
nd HL35464 and American Heart Association grant 0430202N.t
Manuscript received January 6, 2006; revised manuscript received March 17, 2006,
ccepted March 20, 2006.easuring oxLDL are difficult to obtain and commonly
sed in vitro measurements of oxLDL (6,7) are time consum-
ng and not practical for large studies with stored samples.
ecently, direct measurement of circulating oxLDL in plasma
y either an in-house enzyme-linked immunosorbent assay
ELISA) or a commercial ELISA kit provided by Mercodia
Winston-Salem, North Carolina) with the monoclonal
ntibody 4E6 have been used in many case-control, cross-
ectional (8–17) and some prospective studies (18–21).
hese studies suggest that oxLDL is positively associated
ith coronary heart disease (CHD) and related risk factors.
owever, large prospective studies including men and
omen designed to evaluate this marker as an independent
redictor of CHD are lacking.
Measurement of LDL-cholesterol (LDL-C), high-density
ipoprotein-cholesterol (HDL-C), and triglycerides are tradi-
ionally recommended lipid screening tests for CHD; there-
ore, it is important to examine whether oxLDL can predict
HD independent of these lipid markers. Several prospec-ive studies have suggested that apolipoprotein B100
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Circulating oxLDL and Risk of CHD September 5, 2006:973–9apoB), a marker of the number of pro-atherogenic particles
22,23), was the strongest predictor of CHD. Because the
ntibody 4E6 is specific for oxidized apoB (8), it is impor-
ant to determine whether this marker of oxidation is
ndependent of and adds prognostic information beyond
poB itself. None of the previous studies using the same
ntibody has evaluated this issue. Furthermore, several
tudies do suggest that total cholesterol (TC)/HDL-C
atio, a major lipid index, is better than TC, LDL-C,
DL-C, or triglycerides alone; it is easily obtained and one
f the most powerful important risk factors for CHD
24,25). Therefore, we also compared oxLDL and TC/
DL-C ratio.
ETHODS
tudy population and collection of blood samples. HPFS
HEALTH PROFESSIONALS FOLLOW-UP STUDY). The HPFS
s a prospective cohort study of diet, CHD, and cancer
onducted among 51,529 U.S. male health professionals
ho were 40 to 75 years old at baseline in 1986. Health
nformation, including reports of diagnosed heart disease,
as obtained at baseline and assessed biennially by
ollow-up questionnaires. In 1993 and 1994 we sent veni-
uncture kits to participants, and 18,140 men returned
pecimens on ice with an overnight courier. Multiple
liquots of plasma were stored in liquid nitrogen freezers for
uture nested case-control analyses. The men who returned
lood samples were not substantially different from the
emaining men in the cohort except that the prevalence of
urrent smoking was slightly lower among those who
eturned blood samples. We identified 16,453 men who
ere free of cardiovascular diseases and cancer for future
ested case-control studies.
HE NURSES’ HEALTH STUDY I. The Nurses’ Health Study I
ohort, established in 1976, consists of 121,700 female
egistered nurses 30 to 55 years of age who provided
nformation on medical history and lifestyle factors at
aseline and on subsequent biennial questionnaires. In 1989
nd 1990, we collected blood samples from 32,826 cohort
embers who were then 43 to 69 years of age. Whole blood
as shipped, processed, and stored by the methods de-
cribed previously. The women who returned blood samples
Abbreviations and Acronyms
ApoB  apolipoprotein B100
CHD  coronary heart disease
CI  confidence interval
ELISA  enzyme-linked immunosorbent assay
HDL-C  high-density lipoprotein-cholesterol
LRT  likelihood ratio test
MI  myocardial infarction
oxLDL  oxidized low-density lipoprotein
OR  odds ratio
RR  relative risk
TC  total cholesterolere not substantially different from the remaining women sn the cohort. We identified 28,601 women among those
ho returned samples who were free of cardiovascular
isease and cancer for our nested case-control study. The
tudy was approved by the institutional review board of
righam and Women’s Hospital, Boston.
scertainment of cases and selection of control subjects.
he assessment of nonfatal myocardial infarction (MI) and
atal CHD and selection of control subjects are described in
etail elsewhere (26,27). Briefly, when an MI was reported
n a biennial follow-up questionnaire, we sought permission
o review medical records. For confirmation of cases of MI,
e used World Health Organization criteria, which require
ymptoms plus either diagnostic electrocardiographic
hanges or elevated cardiac enzymes. The MIs of undeter-
ined date were not included in this analysis.
The end point for this study comprised incident cases of
onfatal MI and fatal CHD that occurred before February
000 for men and before June 1998 for women. We
onfirmed 266 cases in men and 235 cases in women among
he “at risk” participants. Each case was matched by year of
ge, month of blood draw, and smoking status (never, past,
urrent) to 2 control subjects who were free of CHD at
he time of the case diagnosis. All women were also
atched for fasting status (lower/higher than 8 h) before
lood draw. All assays were conducted without knowl-
dge of the case/control status. Matched case-control trip-
ets were handled identically and together and assayed in the
ame analytical run.
ssessment of medical history, lifestyle, and dietary
actors. Questions related to disease and lifestyle factors
ere sent out every 2 years, and a semiquantitative food
requency questionnaire was sent out every 4 years. For
utrients and other lifestyle characteristics, such as body
ass index (BMI) and physical activity, we used the
nformation from the time when subjects’ blood was col-
ected (1994 for men and 1990 for women). The validity
nd reproducibility of self-reported lifestyle characteristics
nd semiquantitative food frequency questionnaire have
een previously reported (28–32).
easurement of oxLDL, apoB, other lipids, and inflam-
atory markers. The oxLDL was measured by a sandwich
LISA kit with the monoclonal antibody 4E6 (Mercodia).
he antibody 4E6 is especially against an epitope in the
poB-100 moiety of oxLDL that is formed from substitu-
ion of lysine residues of apoB-100 with aldehydes (18). The
oefficient variations of the intra- and inter-assay for mea-
urement of oxLDL were 8%. Total apoB was measured
y an immunoturbidimetric technique on the Hitachi 911
nalyzer (Roche Diagnostics, Indianapolis, Indiana). Total
holesterol, HDL-C, LDL-C, and triglycerides were mea-
ured by standard method with reagent from Roche Diag-
ostics and Genzyme (Cambridge, Massachusetts). Soluble
umor necrosis factor (TNF)-alpha receptors types 1 and 2
sTNF-R1 and sTNF-R2) and C-reactive protein was
easured by latex-enhanced immunoturbidimetric assay
rom Denka Seiken (Tokyo, Japan) on the Hitachi 911
ystem. Interleukin-6 was measured by ELISA (R&D
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ions for apoB, other lipids, and inflammatory markers were
4% to 9%. The laboratory used for analysis is certified by
he Centers for Disease Control and Prevention/National
eart, Lung, and Blood Institute Lipid Standardization
rogram.
tability of oxLDL in whole blood stored on ice up to
6 h. As described earlier, participants sent whole blood
hipped on ice via overnight courier from across the country.
o assess the stability of oxLDL, we conducted a pilot study
hat mimicked these conditions and found that there was no
egradation or increase in the measurement of oxLDL
hen assessed at baseline, 24 h, and 36 h after whole blood
emained on ice (33).
tatistical analysis. BASELINE CHARACTERISTICS. For
aseline variables, we calculated means, medians, or propor-
ions for cases and control subjects. We assessed statistical
ignificance by chi-square tests for categorical variables. We
sed Wilcoxon signed-rank tests for non-normally distrib-
ted variables and 2 sample t tests for normally distributed
ariables and the age-adjusted, partial Spearman rank-
orrelation coefficient to assess the associations between
xLDL and other variables.
SSOCIATION OF oxLDL WITH RISK OF CHD. We catego-
ized participants into quintiles according to the distribution
f plasma levels of oxLDL in the control participants. We
sed conditional logistic regression analyses with and with-
ut adjustment for traditional cardiovascular risk factors,
ncluding family history of MI, alcohol intake, BMI, phys-
cal activity, and history of hypertension or high cholesterol.
ests for trends were performed by entering a single
ontinuous variable assigned as the median value for each
uintile.
OMPARISON OF oxLDL WITH apoB AND OTHER LIPIDS. To
xamine whether oxLDL captures information beyond
poB or TC/HDL-C ratio, we compared the full model
hat included oxLDL and either apoB or TC/HDL-C ratio
o the reduced model without oxLDL with a likelihood
atio test with 4 df. Oxidized LDL and other lipid markers
apoB and TC/HDL-C ratio) were included as quintiles
ith 4 dummy variables. With a similar approach, we
xamined whether apoB or TC/HDL-C ratio adds addi-
ional information beyond oxLDL. To pool the relative risk
RR) estimates for men and women, we used the weighted
verage of estimates with the DerSimonian and Laird
andom effects model (34).
Because of the linear relationship of the oxLDL, apoB,
nd TC/HDL-C with risk of CHD, to reduce residual
onfounding, we also fit the aforementioned models with
xLDL, apoB, and TC/HDL-C ratio as continuous, linear
ariables.
ESULTS
aseline characteristics. We compared characteristics at
lood draw between cases and control subjects (Table 1). sevels of oxLDL at baseline were significantly higher
mong cases than control subjects and also significantly
orrelated with all lipid parameters. The correlation be-
ween oxLDL and apoB was 0.59 in men and 0.44 in
omen; for TC/HDL-C ratio, the correlations were 0.40 in
en and 0.65 in women (Table 2). The oxLDL was
odestly correlated with inflammatory markers in women
ut not in men.
ssociation of oxLDL with risk of CHD and comparison
f oxLDL with apoB and TC/HDL-C ratio. As com-
ared with the lowest quintile, the highest quintile of
xLDL was significantly associated with an increased risk of
HD in both crude and multivariate-adjusted models
Table 3) for both men and women. However, the RRs were
ubstantially attenuated and no longer significant after
djustment for LDL-C, HDL-C, and triglycerides.
When oxLDL and apoB were adjusted simultaneously,
xLDL was no longer predictive; whereas the association of
poB with CHD risk remained significant after adjustment
or oxLDL. The multivariate RR between extreme quintiles
or oxLDL was 1.31 (95% confidence interval [CI] 0.67 to
.57) in men and 1.75 (95% CI 0.77 to 4.01) in women after
djustment of apoB. As shown in Table 4, in both men and
omen, the results of the likelihood ratio test (LRT)
uggested that the full model with oxLDL and apoB was
ignificantly or marginally significantly different from the
odel without apoB (with only oxLDL) (pLRT  0.004 for
en and pLRT 0.06 for women). However, the full model
as not significantly different from the model without
xLDL (with only apoB) in men (pLRT  0.5) or women
pLRT  1.0). These results indicate that apoB added
nformation beyond oxLDL, whereas oxLDL had little
redictive capacity beyond apoB in either men or women.
To directly compare oxLDL with apoB, we also entered
oth oxLDL and apoB in the multivariate model simulta-
eously as continuous variables. In men, the odds ratio
OR)/1 SD increase was 1.05 (95% CI 0.85 to 1.30; p 
.7) for oxLDL and 1.66 (95% CI 1.33 to 2.09; p 0.0001)
or apoB. In women, the OR/1 SD increase was 1.04 (95%
I 0.77 to 1.40; p 0.8) for oxLDL and 1.73 (95% CI 1.25
o 2.41; p  0.0001) for apoB. Again, this suggested that
poB was a stronger predictor than oxLDL.
We performed similar analyses to compare oxLDL versus
C/HDL-C ratio and found similar patterns. The risk of
xLDL between extreme quintiles after adjustment for
C/HDL-C ratio was reduced to 1.70 (95% CI 0.93 to
.13) in men and 1.17 (95% CI 0.51 to 2.68) in women
Tables 3 and 4). However, the RR of TC/HDL-C ratio
etween extreme quintiles was 2.82 (95% CI 1.48 to 5.38)
n men and 4.30 (95% CI 1.76 to 10.52) in women after
djustment for oxLDL (Table 4). With the likelihood ratio
est, we also found that oxLDL did not add any information
eyond TC/HDL-C ratio, but TC/HDL-C ratio added
ignificant information beyond oxLDL (Table 4).
Similarly, we entered oxLDL and TC/HDL-C ratio as
ontinuous variables simultaneously in the model and found
imilar results. In men, the OR/1 SD increase was 1.25
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Circulating oxLDL and Risk of CHD September 5, 2006:973–995% CI 1.04 to 1.50; p  0.02) for oxLDL and 1.44 (95%
I 1.19 to 1.75; p  0.0002) for TC/HDL-C ratio. In
omen, the OR/1 SD increase was 1.16 (95% CI 0.85 to
.47; p  0.4) for oxLDL and 1.36 (95% CI 1.13 to 1.62;
 0.0009) for TC/HDL-C ratio.
In both men and women, additional adjustment for
nflammatory markers in multivariate models did not ap-
reciably alter the RRs for oxLDL.
When we combined the results for the men and women
ith a random effects model, the RR for oxLDL was
arginally significant in the multivariate analysis after
djustment for apoB or TC/HDL-C ratio. The RR for the
ighest versus the lowest quintile was 1.47 (95% CI 0.87 to
.48), p for trend 0.06 after adjustment for apoB; and the
R was 1.49 (95% CI 0.71 to 2.07), p for trend 0.02 after
djustment for TC/HDL-C ratio.
ISCUSSION
e found that the measurement of circulating oxLDL with
he 4E6 antibody, the most widely used antibody for this
ssay, predicted the risk of CHD in a large prospective
etting including men and women. However, this associa-
able 1. Baseline Characteristics and Biochemical Parameters
Characteristics
Men
Cases
(n  266)
Control Subjects
(n  532)
Demographic, History
ean age (yrs) 57.7  8.4 57.7  8.3
ody mass index (kg/m2) 26.2  3.5 25.7  3.5
hysical activity (METS/week) 22.8  42.1 26.6  43.6
lcohol consumption (g/day) 5.6  15.6 7.0  17.3
istory of hypertension (%) 42 31
istory of high cholesterol (%) 49 41
istory of diabetes (%) 8 5
amily history of MI (%) 15 11
moking status (%)
Never smoked 37 37
Former smoker 46 47
Current smoker 12 11
se of aspirin (%) 39 35
ostmenopausal hormone use (%)
ostmenopausal status (%)
Plasma Biomarker
xidized LDL (U/l) 76.5  25 70.1  24
otal cholesterol (mg/dl) 215  40 205  38
riglycerides (mg/dl) 152  117 119  121
DL cholesterol (mg/dl) 42  11 46  12
DL cholesterol (mg/dl) 136  36 127  31
otal/HDL cholesterol 5.4  1.4 4.7  1.4
polipoprotein B (mg/dl) 104  24 92  22
-reactive protein (mg/l) 1.68  5.1 1.08  6.4
L-6 (pg/ml) 1.86  15.0 1.53  11.1
TNFR1 (pg/ml) 1514  501 1505  541
TNFR2 (pg/ml) 2992  868 2944  870
alues are means for continuous variables and proportions for categorical variables, exc
re shown as medians. Age, smoking status and month of blood drawing were matc
HDL  high-density lipoprotein; LDL  low-density lipoprotein; METS  m
unning 1 h corresponds to about 6 MET); MI  myocardial infarction; sTNF-R1ion was not independent of standard lipid variables. Most (mportantly, this association was not independent of two
owerful predictors, apoB and TC/HDL-C ratio. Con-
ersely, apoB or the TC/HDL-C ratio predicted CHD
ndependent of oxLDL. Even in the pooled analysis, the
ndependent association between oxLDL and CHD was
eak after accounting for lipid variables. These comparisons
ere not done in previous studies using the same antibody
ia ELISA.
The strong positive association found in multivariate
nalyses for oxLDL predicting CHD without adjustment
or lipid markers was similar to that from several previous
tudies that have used antibody 4E6 via either the in-house
LISA or the commercially available ELISA kit provided
y Mercodia. In several case-control and cross-sectional
tudies, oxLDL was associated with CHD (9) or stable
HD (17), higher CHD risk on the basis of the Framing-
am score (12), metabolic syndrome and a greater disposi-
ion to atherothrombotic coronary disease (13), glucose
olerance (15), or greater intima thickness and presence of
laque (14). At least 3 cohort studies and 1 nested-case
ontrol study, which used antibody 4E6, have found that
xLDL was associated with number and the size of plaques
p Value
Women
p Value
Cases
(n  235)
Control Subjects
(n  470)
Behavioral Variables
atching factor 63.3  6.5 63  6.6 Matching factor
0.06 26.7  6.3 25.1  4.6 0.0006
0.07 11  17.4 11.5  18.8 0.2
0.1 0.9  9.6 1.95  10.7 0.0001
0.002 57 28 0.0001
0.02 43 29 0.0002
0.1 14 3 0.0001
0.09 22 13 0.0015
atching factor Matching factor
34 34
34 35
32 31
0.3 45 51 0.13
31 37 0.004
86 83 0.3
an, Median, SD)
0.001 38.7  12 34.4  12 0.002
0.001 236  40 226  40 0.002
0.001 128  91 110  76 0.0001
0.001 52  15 60  17 0.001
0.001 143  34 133  37 0.001
0.001 4.9  1.5 4.0  1.3 0.001
0.001 130  36 115  31 0.001
0.0001 3.1  6.4 2.2  4.8 0.0003
0.009 1.99  12.3 1.63  7.3 0.002
0.8 1452  595 1265  355 0.0001
0.5 2795  981 2487  771 0.0001
ohol, physical activity, C-reactive protein, triglycerides, and interleukin (IL)-6, which
ctors. Body mass index (weight divided by height squared).
c equivalent hours (1 MET corresponds to the energy used for 1 h of quiet sitting,
NF-R2  soluble tumor necrosis factor receptor types 1 and 2., and
M
M
s (Me
ept alc
hed fa20), with MI cases among men (19), with cardio-
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September 5, 2006:973–9 Circulating oxLDL and Risk of CHDransplanted vasculopathy in men and women (18), and
cute CHD events in men (21). However, many of these
tudies were small and lacked the power to control for all
otential confounders and, especially, did not finely adjust
or lipid markers. Most importantly, none of them deter-
ined whether oxLDL was independent of apoB, and only
study (21) adjusted for TC/HDL-C ratio, but their
able 2. Age-Adjusted Spearman Rank Correlation Coefficients
etween Oxidized LDL and Selected Cardiovascular Risk
actors Among Control Subjects (n  532 Men and n  470
omen) at Baseline
Oxidized LDL
Men r Women r
ody mass index 0.07 0.17*
hysical activity 0.04 0.15†
lcohol consumption 0.03 0.12*
otal cholesterol 0.51‡ 0.49‡
riglycerides 0.21‡ 0.45‡
DL cholesterol 0.11* 0.41‡
DL cholesterol 0.55‡ 0.58‡
otal cholesterol/HDL cholesterol ratio 0.40‡ 0.65‡
polipoprotein B 0.59‡ 0.44‡
ipoprotein(a) 0.08* 0.05
-reactive protein 0.03 0.17†
TNF-R1 0.002 0.14†
TNF-R2 0.04 0.12*
L-6 0.05 0.05
p  0.05; †p  0.01; ‡p  0.001.
Abbreviations as in Table 1.
able 3. Relative Risk of Coronary Heart Disease Across Quintil
rofessional Follow-Up Study and 705 Women From the Nurses
1 2
en
Median, U/ml 43.88 57.65
n 38 35
Matching factors only* (95% CI) 1 0.98 (0.57–1.72)
Model 1—multivariate adjusted†
(95% CI)
1 1.01 (0.57–1.79)
Model 1  LDL (quintiles)  HDL
(quintiles)  triglycerides
(quintiles) (95% CI)
1 0.95 (0.51–1.74)
Model 1  apoB (quintiles) (95% CI) 1 0.86 (0.47–2.56)
Model 1  total/HDL cholesterol
(quintiles) (95% CI)
1 0.87 (0.48–1.56)
omen
Median, U/ml 21.61 27.84
n 26 26
Crude matched‡ (95% CI) 1 1.10 (0.58–2.08)
Model 1—multivariate adjusted§
(95% CI)
1 0.93 (0.47–1.85)
Model 1  LDL (quintiles)  HDL
(quintiles)  triglycerides
(quintiles) (95% CI)
1 0.69 (0.33–1.47)
Model 1  apoB (quintiles) (95% CI) 1 0.86 (0.42–1.78)
Model 1  total/HDL cholesterol
(quintiles) (95% CI)
1 0.58 (0.27–1.24)
Matched on age, smoking, and time of blood draw. †Model 1: adjusted for body
holesterol and diabetes, family history of myocardial infarction, and use of aspirin. ‡
dditionally adjusted for fasting status; model 1 for women was additionally adjusted for p
ApoB  apolipoprotein B; CI  confidence interval; other abbreviations as in Table 1nalysis included only men and adjusted for physical activity
nd obesity only as dichotomized variables, leaving the
ossibility of residual confounding.
Inflammatory processes produce oxidative products.
owever, oxLDL can also induce production of monocyte
hemotactic protein-1 and monocyte-colony stimulating
actor and lead to inflammatory response in vascular cells
35–37). Inflammation, reflected by circulating inflamma-
ory markers such as C-reactive protein, are associated with
ncidence of CHD in large prospective studies (27,38).
owever, on the basis of our data, the association for
xLDL is not explained by inflammation, because the risk
f oxLDL did not change after adjustment of any inflam-
atory markers.
The oxLDL is thought to be a mixture of heteroge-
eously modified particles. Many components in LDL can
e oxidized, including apoB, phospholipids, LDL-
holesterol, and unsaturated fatty acids. Therefore, several
ntibodies against different epitopes on LDL have been
enerated, including the most widely used antibody 4E6
gainst oxidized apoB (as used in this report), antibody
OH1a/DLH3 (39), and antibody E06 (40,41) against
xidized phospholipids. Circulating oxLDL measured via
he antibodies, FOH1a/DLH3, or E06 was not associated
ith apoB (40–42), and oxLDL measured via the antibody
06 was found to be significantly associated with lipopro-
ein(a) (Lp[a]) (41). However, we and several others (14–
Oxidized LDL Among 798 Men From the Health
alth Study
uintile of Oxidized LDL p for
Linear
Trend3 4 5
66.65 77.38 103.46
60 62 71
.61 (0.98–2.65) 1.88 (1.12–3.13) 2.39 (1.42–4.05) 0.0001
.70 (1.01–2.87) 2.10 (1.22–3.63) 2.56 (1.46–4.50) 0.0001
.55 (0.87–2.77) 1.52 (0.80–2.87) 1.64 (0.83–3.25) 0.1
.27 (0.72–2.25) 1.40 (0.76–2.60) 1.31 (0.67–2.57) 0.3
.42 (0.82–2.43) 1.47 (0.82–2.65) 1.70 (0.93–3.13) 0.03
33.03 37.9 47.63
49 58 76
.18 (1.23–3.88) 2.52 (1.43–4.44) 4.16 (2.26–7.65) 0.0001
.81 (0.97–3.38) 1.78 (0.94–3.36) 2.84 (1.42–5.66) 0.0005
.20 (0.59–2.43) 0.97 (0.44–2.15) 1.53 (0.65–3.57) 0.1
.45 (0.74–2.86) 1.18 (0.56–2.49) 1.75 (0.77–4.01) 0.1
.99 (0.48–2.01) 0.7 (0.31–1.55) 1.17 (0.51–2.68) 0.3
index, physical activity, alcohol consumption, history of high blood pressure, high
ed on age, smoking, time of blood draw, and fasting status. §Model 1 for men wases of
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ignificantly associated with apoB but not with Lp(a). These
ata do highlight the importance of antibody selection,
ecause different antibodies might reflect different compo-
ents of oxLDL.
Two cross-sectional studies (41,42), with the antibody
OH1a/DLH3 and the antibody E06 to detect oxLDL,
ound that oxLDL was significantly associated with CHD
fter adjustment for apoB. Because there is 1 apoB particle/
DL particle, it is important to adjust apoB even if
ntibodies FOH1a/DLH3 and E06 are not specifically
gainst apoB. These two studies indirectly support our
ontention that antibodies other than the most widely used
ntibody 4E6 could be alternative choices. Alternatively, a
ombination of antibodies should be evaluated simulta-
eously in future prospective studies.
We think our data have clinical implications for several
easons. Our study is the largest prospective study including
en and women, and we compared oxLDL with other lipid
arkers after finely controlling multiple CHD risk factors.
iven that so many studies that had used this 4E6 antibody
ound a strong relationship between this marker and CHD
ithout finely controlling lipid variables in their analyses,
ur results for the first time raise the questions of whether
e should add additional costs to measure oxLDL with this
ntibody for screening and to justify the potential improve-
ent in risk prediction over the currently available lipid risk
actors. Total cholesterol and HDL-C are standard lipid
easures, and TC/HDL-C ratio can be directly calculated
t no incremental cost beyond usual lipid evaluation. Mea-
urement of apoB is also easier and less expensive than
easurement of oxLDL via ELISA with this 4E6 antibody.
oth TC/HDL-C ratio and apoB are more powerful
redictors of CHD than oxLDL. Taken together, measure-
ent of oxLDL via ELISA with different antibodies should
e further evaluated before this marker is applied in clinical
ractice.
Our study has several strengths and limitations. We had
large sample size, included both men and women, and we
ccounted for several well-measured confounders in our
nalyses, including multiple markers of lipids and inflam-
able 4. OxLDL in Comparison With Mutually Adjusted ApoB
Mutually Adjusted Marker 1
Marker RR (95% CI) pLRT
en OxLDL 1.31 (0.67–2.57) 0.5
p for linear trend  0.3
OxLDL 1.70 (0.93–3.13) 0.1
p for linear trend  0.03
omen OxLDL 1.75 (0.77–4.01) 1.0
p for linear trend  0.1
OxLDL 1.17 (0.51–2.68) 0.2
p for linear trend  0.3
ultivariates included: body mass index, physical activity, alcohol consumption, hi
nfarction, and use of aspirin. The p value of the likelihood ratio test (LRT) is for a
arker with the model without the corresponding marker with 4 def. Each marker
RR  relative risk in the highest compared with the lowest quintile of each maration. Additionally, we collected plasma samples beforehe diagnosis of disease, which should reduce the impact of
HD on level of oxLDL at baseline. However, other
ntibodies for measuring oxLDL were not available from
hese studies at the time of this analysis. We recognize that
he risk of CHD in our cohorts might be lower than in other
opulations. However, major cohort studies, such as the
ramingham Heart Study, have also not relied on national
amples. The advantages of our cohorts are that our partic-
pants had a high level of education and can provide
igh-quality and valid information on self-administrated
orms. Data validity is the chief prerequisite for generalizing
esults. The range of lifestyle and biochemical variables in
ur cohorts is quite broad. In previous analyses we observed
hat the associations for CHD and other diseases are very
imilar to those found in other broad-based U.S. popula-
ions.
In conclusion, we found that circulating oxLDL,
easured by the most widely used antibody 4E6, can
redict the risk of CHD but not independent of the two
trongest risk factors, apoB and TC/HDL-C ratio, or
ther conventional lipid markers, including LDL-C,
DL-C, and triglycerides. Apolipoprotein B100 and TC/
DL-C ratio are more predictive in development of CHD
han oxLDL. Measurement of oxLDL with multiple anti-
odies is needed in future large-scale, prospective studies to
ddress the long-desired question of whether oxLDL is an
ndependent risk factor of CHD.
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